Fertility and Sterility, 54(1), 178-179, 1990
Diagnosis and treatment of premenstrual syndrome
Author affiliations
- Vanderbilt University Medical Center ROR
Abstract not indexed. Read at publisher
Topics
Abraham Hargrove premenstrual syndrome diagnosis treatment, PMS diagnosis treatment guidelines fertility sterility, premenstrual syndrome clinical management review 1990, premenstrual syndrome hormonal evaluation treatment, PMS diagnostic criteria clinical assessment, premenstrual syndrome nutritional hormonal therapy, Abraham GE premenstrual syndrome nutritional deficiency, menstrual cycle disorders premenstrual symptoms management, premenstrual syndrome differential diagnosis approach, PMS treatment options review fertility and sterility
PMID 2358087 2358087 DOI 10.1016/s0015-0282(16)53661-9 10.1016/s0015-0282(16)53661-9 Abraham et al. 1990, Abraham 1990
Cite this article
Abraham, G. E., & Hargrove, J. T. (1990). Diagnosis and treatment of premenstrual syndrome. Fertility and Sterility, 54(1), 178-179. https://doi.org/10.1016/s0015-0282(16)53661-9
Abraham GE, Hargrove JT. Diagnosis and treatment of premenstrual syndrome. Fertil Steril. 1990;54(1):178-179. doi:10.1016/s0015-0282(16)53661-9
Abraham, G. E., and J. T. Hargrove. "Diagnosis and treatment of premenstrual syndrome." Fertility and Sterility, vol. 54, no. 1, 1990, pp. 178-179.
Keywords
Alprazolam/therapeutic Use, Female, Humans, Premenstrual Syndrome/diagnosis/drug Therapy, Alprazolam
Related articles
Prescribing Safety · Off-Label Prescribing
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review
Dimmock PW et al., 2000 · Lancet ·
Selective serotonin-reuptake inhibitors (SSRIs) are increasingly being used as first-line therapy for severe premenstrual syndrome (PMS). We undertook a meta-analysis on the efficacy of SSRIs in this disorder. We searched medical and scientific databases, approached pharmaceutical companies, and reviewed citations of relevant articles to identify 29 studies of the use of SSRIs in PMS. 14 were excluded (no placebo group, preliminary report of included trial, or low quality). 15 randomised placebo-controlled trials were included. Information on study design, participants, drugs used and dosing regimens, outcome measures, side-effects, and sources of funding was extracted. Standardised mean differences between treatment and placebo groups were calculated to obtain an overall estimate of efficacy. The primary outcome measure was a reduction in overall PMS symptoms. The primary analysis included data on 904 women (570 assigned active treatment and 435 assigned placebo, including 101 in crossover trials). The overall standardised mean difference was -1.066 (95% CI -1.381 to -0.750), which corresponds to an odds ratio of 6.91 (3.90 to 12.2) in favour of SSRIs. SSRIs were effective in treating physical and behavioural symptoms. There was no significant difference in symptom reduction between continuous and intermittent dosing or between trials funded by pharmaceutical companies and those independently funded. Withdrawal due to side-effects was 2.5 times more likely in the active-treatment group than in the placebo group. SSRIs are an effective first-line therapy for severe PMS. The safety of these drugs has been demonstrated in trials of affective disorder, and the side-effects at low doses are generally acceptable.
Prescribing Safety · Off-Label Prescribing
The effects of vitamin B6 supplementation on premenstrual symptoms
Kendall KE et al., 1987 · Obstet Gynecol ·
A double-blind controlled study of the effects of vitamin B6 supplementation on premenstrual symptoms was conducted. Fifty-five women who reported moderate to severe premenstrual mood changes participated in the study. Symptoms were monitored prospectively through daily home record-keeping over a one-month baseline period followed by two months of treatment. Subjects were randomly assigned to receive daily supplements of 150 mg of vitamin B6 or placebo over the entire two-month treatment period. Analysis of covariance suggested that even though vitamin B6 may improve premenstrual symptoms related to autonomic reactions (eg, dizziness and vomiting) and behavioral changes (eg, poor performance and decreased social activities), a significant amount of physical and affective symptomatology remained during the premenstrual phase. In light of recently reported, potentially toxic effects of low doses of vitamin B6, our results call for caution in using this therapy for premenstrual symptoms.
Prescribing Safety · Off-Label Prescribing
Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial
Smith S et al., 1987 · Obstet Gynecol ·
A double-blind, placebo-controlled, randomized multiple crossover study was designed to determine the effectiveness of alprazolam in the treatment of premenstrual syndrome. Patients maintained daily diaries of 22 premenstrual symptoms for one pretreatment control cycle and four treatment cycles. Alprazolam 0.25 mg or placebo was administered three times daily from cycle day 20 until the second day of menstruation, at which time the dosage was tapered by one tablet per day to minimize withdrawal effects. The results of the clinical trial indicate that alprazolam is significantly more effective than placebo in relieving the severity of premenstrual nervous tension, mood swings, irritability, anxiety, depression, fatigue, forgetfulness, crying, cravings for sweets, abdominal bloating, abdominal cramps, and headache. The low incidence of side effects makes alprazolam an acceptable treatment for premenstrual syndrome for those women unresponsive to other therapies.
Bone Mineral Density · Measurement
Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol
Tummon IS et al., 1988 · Fertil Steril ·
Lumbar bone mineral density (BMD) was evaluated by dual photon absorptiometry (DPA) in 38 women with laparoscopically diagnosed and staged endometriosis. DPA was performed before and at the completion of 26 weeks of treatment with either gonadotropin releasing hormone agonist (GnRHa) or danazol. Twenty-five women received GnRHa either nasally or subcutaneously and 13 women received danazol 200 mg four times daily by mouth. During treatment amenorrhea and suppressed estradiol levels were observed in all patients. Each patient took a supplement of oral calcium 1 gm daily. DPA (reproducibility +/- 1.5%) was read by a single observer unaware of the treatment assignment of the patient. The mean (+/- standard error) of the entire group prior to treatment was 98.8% +/- 0.03% of a control population of women from the same geographic area matched for race, age, and weight. At the completion of treatment, BMD was slightly decreased in the GnRHa group and marginally increased in the danazol group but neither change was significant. Women with endometriosis have lumbar BMD in the normal range and ovarian suppression with either GnRHa or danazol produces no significant change in BMD.